Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support Intervention
University of Chicago · with Tulane University, University of Alabama at Birmingham · NCT05723653
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–49 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 900
- US sites recruiting
- 4
- Study start
- February 13, 2023
- Record last updated
- April 8, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this Hybrid Type I effectiveness-implementation trial is to test an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among people living with HIV aged 18-49.
Being studied: Social Network Support Intervention
Conditions: HIV Seropositivity
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria for Index Participants
- Aged 18-49 years old, inclusive
- Speak English
- Own a cell phone not shared with anyone else
- Have missed at least one HIV care scheduled visit or have not been virally suppressed in the past 24 months.
- Resides in Chicagoland, Illinois or Alabama
Exclusion Criteria for Index Men
- If a participant fails to meet all inclusion criteria
Inclusion Criteria for Support Confidants
- Index agrees to engage the Support Confidant
- Age 18 years or older
- Speaks English
- Owns a cell phone not shared with others
- Is not a romantic/sexual partner of the Index participant
Exclusion Criteria
- Romantic/Sexual partners of Index participant
- Relationship strain or abuse present in Index-Support Confidant relationship
Recruiting US locations
Birmingham AIDS Outreach
Birmingham, AL 35233
Site contact: Emma S Kay, PhD · emma@mcwc-bao.org
Thrive Alabama
Huntsville, AL 65801
Site contact: Erin Bortel · ebortel@thrivealabama.org
Howard Brown Health
Chicago, IL 60613
Site contact: Juan Rivera · juanr@howardbrown.org
Chicago Center for HIV Elimination
Chicago, IL 60637
Site contact: Rebecca Eavou · reavour@medicine.bsd.uchicago.edu
Study contacts (from the official record)
- Alida Bouris, PhD · 773-834-4304 · abouris@uchicago.edu
- David S Batey, PhD · 504-862-3485 · dsbatey@tulane.edu
Similar studies in Alabama
All healthy volunteers studies in Alabama →- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- Birmingham, AL + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Gadsden, AL + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Regeneron Pharmaceuticals
- Location
- Birmingham, AL + 5 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019)
Merck Sharp & Dohme LLC
- Location
- Anniston, AL
- Eligibility basics
- Ages 18–65